Beijing, July 23 (Xinhua) - China is currently conducting the research and development of monovalent and multivent vaccines against the omicrone variants through Multiple technical routes.
Chinese vaccines still protect against disease and death caused by omicrones variants, said Feng Zijian, executive vice president and general secretary of the Chinese Preventive Medicine Association . Feng made the comments at a press conference held by the Joint Prevention and Control Mechanism of the State Council against COVID-19 on Saturday.
Monovalent inactivated vaccines are experiencing clinical trials in clinical trials in Zhejiang, Hunan and Hong Kong.
Tetravalent recombinant protein vaccines have obtained approved documents for phase III clinical trials in the United Arab Emirates, and have taken the relevant studies. out.
China is promoting its investigation and development of vaccines against OMICRON variants quickly and constantly, the official said. ENITEM
Categories:
Beijing Multipl Zhejiang
